Discovering The Importance of ICAM4 Glycoprotein in Human Blood

Target Name: ICAM4

NCBI ID: G3386

ICAM4

Discovering The Importance of ICAM4 Glycoprotein in Human Blood

The Landsteiner-Wiener blood group glycoprotein (ICAM4) is a protein that is found on the surface of red blood cells. It is a type of carbohydrate antigen that is present on the surface of nearly all human red blood cells and is responsible for the antigenic diversity of the blood group. There are four different blood groups that have been identified based on the presence of different ICAM4 antigens: A, B, AB, and O. Each blood group has its own unique surface antigens that are present on the ICAM4 protein.

ICAM4 is an important protein that plays a critical role in the immune system. It is one of the proteins that is involved in the recognition of foreign substances that have entered the body. When a foreign substance binds to ICAM4, it causes the cell to become activated and to start an immune response. This is a key part of the body's immune system and helps to protect the body against infection and disease.

ICAM4 is also an important biomarker for some diseases. For example, ICAM4 has been used as a marker for diseases such as sickle cell anemia, hemoglobinopathy, and thalassemia. These diseases are caused by abnormal levels of the ICAM4 protein or to the genes that encode it.

One of the potential uses for ICAM4 as a drug target is for the treatment of sickle cell anemia. sickle cell anemia is a genetic disorder that is characterized by the production of abnormal hemoglobin. This causes the red blood cells to become sickle-shaped and to have a much lower capacity to carry oxygen to the body's tissues. The symptoms of sickle cell anemia can be severe and include pain, jaundice, and episodes of acute illness.

ICAM4 has been shown to be an effective target for the treatment of sickle cell anemia because it is present at higher levels in the red blood cells of people with the disease than in healthy cells. Additionally, studies have shown that ICAM4 can inhibit the production of abnormal hemoglobin in sickle cell anemia cells, which can lead to the production of healthier red blood cells.

Another potential use for ICAM4 as a drug target is for the treatment of other diseases. For example, ICAM4 has been shown to be an effective marker for the diagnosis of hemoglobinopathy, which is a group of genetic disorders that affect the production of hemoglobin. These disorders can include sickle cell anemia, thalassemia, and myelodysplastic syndromes.

ICAM4 has also been shown to be an effective biomarker for the diagnosis of some other diseases, such as thalassemia. Thalassemia is a genetic disorder that is characterized by the production of abnormal hemoglobin. It can cause a wide range of symptoms, including anemia, fatigue, and joint pain.

In addition to its potential uses as a drug target and biomarker, ICAM4 is also an important protein that is involved in the immune system. It is one of the proteins that is involved in the recognition of foreign substances that have entered the body. When a foreign substance binds to ICAM4, it causes the cell to become activated and to start an immune response. This is a key part of the body's immune system and helps to protect the body against infection and disease.

Overall, ICAM4 is a protein that is important for many different functions in the body. It is an effective marker for the diagnosis of sickle cell anemia and other diseases, and it is also an important part of the immune system. As a result, ICAM4 is an attractive target for

Protein Name: Intercellular Adhesion Molecule 4 (Landsteiner-Wiener Blood Group)

Functions: ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). ICAM4 is also a ligand for alpha-4/beta-1 and alpha-V integrins

The "ICAM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ICAM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets